MET/VEGFR-2 inhibitor GSK1363089 A substance being studied in the treatment of cancer. MET/VEGFR-2 inhibitor GSK1363089 blocks enzymes involved in the growth and spread of tumor cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called foretinib and XL880. |